ANI Pharmaceuticals
ANIP
163 hedge funds and large institutions have $422M invested in ANI Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 46 increasing their positions, 54 reducing their positions, and 13 closing their positions.
131% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 13
25% more capital invested
Capital invested by funds: $337M → $422M (+$85.4M)
12% more funds holding
Funds holding: 146 → 163 (+17)
1.12% more ownership
Funds ownership: 55.1% → 56.22% (+1.1%)
15% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 54
82% less call options, than puts
Call options by funds: $4.01M | Put options by funds: $22.4M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$16.7M |
| 2 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$5.88M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.01M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$2.92M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$14.2M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$8.92M |
| 3 |
FIM
Foresters Investment Management
New York
|
-$4.88M |
| 4 |
Renaissance Technologies
New York
|
-$3.55M |
| 5 |
JP Morgan Chase
New York
|
-$3.2M |
ANIP Hedge Fund Activity: Q4 2017 in Review
163 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2017, worth a combined $422M — up 25% from $337M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ANIP positions and 13 closed out — a net gain of 17 holders — while 46 added to existing stakes and 54 trimmed.
The largest buyer was Invesco, adding an estimated $16.7M. The largest seller was First Manhattan, cutting an estimated $14.2M.
- 163 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2017, up from 146 in Q3 2017.
- Funds reported $422M of ANI Pharmaceuticals stock for Q4 2017, up 25% quarter-over-quarter.
- 30 funds opened new ANI Pharmaceuticals positions in Q4 2017 and 13 closed out, a net change of +17 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2017 was Invesco, an estimated $16.7M added.
- The largest ANI Pharmaceuticals seller in Q4 2017 was First Manhattan, an estimated $14.2M sold.
Based on aggregated 13F filings for Q4 2017.